Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05667506 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Jul 30, 2025 to May 30, 2025
    • Study completion date: Dec 30, 2026 to May 30, 2027
    v6
  2. Primary completion date: Dec 30, 2024 to Jul 30, 2025v5
  3. Primary completion date: Jun 30, 2024 to Dec 30, 2024
    • Study completion date: Dec 30, 2025 to Dec 30, 2026
    v4
  4. Study sites: 1 to 9v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 6, 2023 to Feb 7, 2023
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
Trial Details
NCT Number NCT05667506
Lead Sponsor Juventas Cell Therapy Ltd.
Conditions
(from sponsor)		 B-cell Acute Lymphoblastic Leukemia
Related terms Burkitt Lymphoma
Enrollment 47 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov